FBLG — Fibrobiologics Balance Sheet
0.000.00%
- $163.27m
- $155.57m
Annual balance sheet for Fibrobiologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Cash and Short Term Investments | 0.407 | 2.27 | 9.16 |
Net Total Receivables | — | 0.3 | 0 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 0.468 | 2.63 | 9.21 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | — | 2.2 | 2.61 |
Total Assets | 0.468 | 4.82 | 11.8 |
Payable / Accrued | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 1.76 | 7.07 | 9.18 |
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 1.76 | 8.82 | 10.6 |
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | -1.29 | -4 | 1.25 |
Total Liabilities & Shareholders' Equity | 0.468 | 4.82 | 11.8 |
Total Common Shares Outstanding |